LEF1 and COVID-19: Also, almost two-thirds of patients who reported cardiovascular or neurological complications at follow-up also declared having comorbidities at the time of COVID-19 diagnosis, limiting the strength of the association between LEF1-AS1 levels and the de novo development of complications post COVID-19.